In September, an inquest was opened into the death, with reviews in March and August of this year, Norfolk Police marking the one-year anniversary of the collision by once again appealing for anyone who may not have come forward last year to do so now.
The A11 dual carriageway in Norfolk, while a popular time trialling venue for local clubs, has witnessed a number of collisions involving racers and drivers. A year before this fatal collision, in 2021, a female cyclist wasafter being hit by a van driver from behind during a time trial on the section of the A11 between Snetterton and Shropham.
"For a number of years, we have warned the groups about the significant dangers in running time trials on major A-roads. But from a legal perspective there is nothing we can do to stop them," the spokesperson said. A month later, however, the East District branch of Cycling Time Trials, the national governing body for time trials in England and Wales, suspended races on dual carriageways following the death.
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: i newspaper - 🏆 8. / 89 Read more »
Carer raped elderly woman, 76, with dementia in her bedroom, trial hearsCarer raped elderly woman, 76, with dementia in her bedroom before telling her he would 'come back and finish the job', trial hears
Source: MENnewsdesk - 🏆 23. / 69 Read more »
TikToker murder trial: Two defendants face dangerous driving chargesRaees Jamal and Rekan Karwan plead not guilty to new charges of death by dangerous driving.
Source: bbcemt - 🏆 120. / 51 Read more »
The value of pre-symptomatic genetic risk assessment for age-related macular degeneration: the Moran AMD Genetic Testing Assessment (MAGENTA) study—a study protocol for a randomized controlled trial - TrialsBackground Age-related macular degeneration (AMD) is an irreversible blinding eye condition with complex genetic and environmental etiologies. Genetic testing for AMD for previously identified multiple-risk single nucleotide polymorphisms can help determine an individual’s future susceptibility. However, such testing has been discouraged until evidence shows that providing such information to symptomatic or pre-symptomatic individuals will alter their disease course. Therefore, we designed this study to investigate whether knowledge of AMD risk could stimulate the adoption of a healthier lifestyle that could lower the incidence of AMD later in life. We hypothesize that pre-symptomatic individuals informed of a high genetic risk of AMD are more likely to make quantifiable, positive lifestyle changes relative to participants informed of lower genetic risk or randomized to deferred disclosure of genetic testing results. Methods The Moran AMD Genetic Testing Assessment (MAGENTA) study is a phase 2, single-center, prospective, double-masked, randomized controlled trial conducted at the John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, USA. Participants are randomized by a 3:1 allocation ratio to immediate and deferred disclosure groups and followed for 12 months. Skin, ocular, and serum carotenoid status, as well as nutritional and social surveys, are assessed at study visits. Skin carotenoid assessment is by resonance Raman spectroscopy and reflectance spectroscopy, ocular carotenoids are measured with Heidelberg Spectralis autofluorescence imaging and fluorescence lifetime imaging ophthalmoscopy (FLIO), and serum carotenoids are quantified using high-performance liquid chromatography. The primary outcome evaluates changes in skin carotenoid status in response to genetic risk disclosure. The secondary outcomes examine changes in ocular and serum carotenoid status in response to genetic risk disclosure. Also, we will correlate AMD genetic risk with base
Source: BioMedCentral - 🏆 22. / 71 Read more »